Multiple Sclerosis - Drug Pipeline Analysis and Market Forecasts to 2015

GlobalData, the industry analysis specialist, has released a new report, “Multiple Sclerosis – Drug Pipeline Analysis and Market Forecasts to 2015”. The report is an essential source of information and analysis on the global multiple sclerosis (MS) market. The report identifies the key trends shaping and driving the global MS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global MS sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The Scope of the report includes:
- Annualized global multiple sclerosis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include immunomodulator and anti-inflammatory, cytokine and cytokine-receptor targetters, ion channel targetters, metabolic pathway's enzymes targetters, remyelination stimulator and demyelination inhibitor, and neurotransmitters targetters.
- Analysis of the current and future market competition in the global multiple sclerosis market. Key market players covered are Biogen idec, Merck Serono, Sanofi Aventis, AstraZeneca and Glenmark Pharmaceuticals Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with multiple sclerosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global multiple sclerosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global multiple sclerosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global multiple sclerosis market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS


1.1 LIST OF TABLES


1.2 LIST OF FIGURES


2 MARKET CHARACTERIZATION

2.1 Overview
2.2 Multiple Sclerosis Market Size
2.3 Multiple Sclerosis Market Forecast and CAGR
2.4 Drivers and Barriers for Multiple Sclerosis Market
  2.4.1 Drivers for Multiple Sclerosis Market
  2.4.2 Barriers for Multiple Sclerosis Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Multiple Sclerosis Market
  3.3.1 Copaxone (Glatiramer Acetate)
  3.3.2 Avonex/Rebif (Interferon Beta)
  3.3.3 Tysabri (Natalizumab)
  3.3.4 Novantrone (Mitoxantrone)
  3.3.5 Betaseron/ Betaferon
3.4 Key Takeaway

4 PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Multiple Sclerosis Therapeutics –Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development for Multiple Sclerosis
  4.4.1 Mylinax (Cladribine Oral Formulation)
  4.4.2 Teriflunomide
  4.4.3 BG-12
  4.4.4 Fingolimod
  4.4.5 Laquinimod
4.5 Multiple Sclerosis Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Multiple Sclerosis Pipeline – Pipeline by Clinical Phases of Development
  4.6.1 Multiple Sclerosis Therapeutics – Regulatory and Phase III Clinical Pipeline
  4.6.2 Multiple Sclerosis Therapeutics-Phase II Clinical Pipeline
  4.6.3 Multiple Sclerosis Therapeutics-Phase I Clinical Pipeline
  4.6.4 Multiple Sclerosis Therapeutics- Pre-Clinical Pipeline
  4.6.5 Multiple Sclerosis Therapeutics- Discovery Pipeline
4.7 Discontinued / Suspended Drugs for Multiple Sclerosis
4.8 Key Takeaway

5 MULTIPLE SCLEROSIS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION


6 MULTIPLE SCLEROSIS MARKET: FUTURE PLAYERS IN MULTIPLE SCLEROSIS MARKET

6.1 Introduction
6.2 Biogen idec
  6.2.1 Overview
  6.2.2 CNS Portfolio
  6.2.3 Multiple Sclerosis Product Portfolio
6.3 Merck Serono
  6.3.1 Overview
  6.3.2 CNS Portfolio
  6.3.3 Multiple Sclerosis Product Portfolio
6.4 Sanofi-aventis
  6.4.1 Overview
  6.4.2 CNS Portfolio
  6.4.3 Multiple Sclerosis Product Portfolio
6.5 AstraZeneca
  6.5.1 Overview
  6.5.2 CNS Portfolio
  6.5.3 Multiple Sclerosis Product Portfolio
6.6 Glenmark
  6.6.1 CNS Portfolio
  6.6.2 Multiple Sclerosis Product Portfolio

7 MULTIPLE SCLEROSIS MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panels Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 LIST OF TABLES

Table 1: Global Multiple Sclerosis Therapeutics Market, Revenue ($m), 2000-2015
Table 2: Global Multiple Sclerosis Therapeutics Market, Revenue ($m), 2000-2015
Table 3: Major Marketed Products Comparison in Multiple Sclerosis Market, 2009
Table 4: Multiple Sclerosis Therapeutics – Most Promising Drugs Under Clinical Development, 2009
Table 5: Multiple Sclerosis Therapeutics – Regulatory and Phase III Clinical Pipeline, 2009
Table 6: Multiple Sclerosis Therapeutics – Regulatory and Phase III Clinical Pipeline (Contd..), 2009
Table 7: Multiple Sclerosis Therapeutics – Phase II Clinical Pipeline, 2009
Table 8: Multiple Sclerosis Therapeutics – Phase II Clinical Pipeline (Contd..), 2009
Table 9: Multiple Sclerosis Therapeutics – Phase II Clinical Pipeline (Contd..), 2009
Table 10: Multiple Sclerosis Therapeutics – Phase I Clinical Pipeline, 2009
Table 11: Multiple Sclerosis Therapeutics – Phase I Clinical Pipeline (Contd..), 2009
Table 12: Multiple Sclerosis Therapeutics – Pre-Clinical Pipeline, 2009
Table 13: Multiple Sclerosis Therapeutics – Pre-Clinical Pipeline (Contd..), 2009
Table 14: Multiple Sclerosis Therapeutics – Pre-Clinical Pipeline (Contd..), 2009
Table 15: Multiple Sclerosis Therapeutics – Discovery Pipeline, 2009

TABLE 16: LIST OF DISCONTINUED DRUGS FOR MULTIPLE SCLEROSIS, 2009

Table 17: Biogen – Neurologic Disorder Marketed Products, 2009
Table 18: Biogen – Neurologic Disorder Pipeline Products, 2009
Table 19: Merck Serono – Neurologic Disorder Marketed Products, 2009
Table 20: Merck Serono – Neurologic Disorder Pipeline Products, 2009
Table 21: Sanofi-Aventis – Neurologic Disorder Marketed Products, 2009
Table 22: Sanofi-Aventis – Neurologic Disorder Pipeline Products, 2009
Table 23: AstraZeneca – Neurologic Disorder Marketed Products, 2009
Table 24: AstraZeneca – Neurologic Disorder Pipeline Products, 2009
Table 25: AstraZeneca – Neurologic Disorder Pipeline Products (Contd…), 2009
Table 26: Glenmark – Neurologic Disorder Pipeline Products, 2009

1.2 LIST OF FIGURES

Figure 1: Global Multiple Sclerosis Market, Revenue ($m), 2000-2015
Figure 2: Opportunity and Unmet Need in the Multiple Sclerosis Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Multiple Sclerosis, 2009
Figure 4: Technology Trends Analytic Framework for the Multiple Sclerosis Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Multiple Sclerosis Pipeline – Description, 2009
Figure 6: Multiple Sclerosis Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Multiple Sclerosis Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Multiple Sclerosis, 2009
Figure 9: Multiple Sclerosis Therapeutics Market – Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
Biogen idec
Merck Serono
Sanofi-aventis
AstraZeneca
Glenmark
Skip to top